
Today we’re sharing a defining moment for @CellularIntelHQ, for cell therapy, and hopefully one day for patients with Parkinson’s. We’re acquiring STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s from @novonordisk, who'll also be investing in CI.


















